Other Events ·
MIRA Pharmaceuticals, Inc. announced on June 17, 2026, the submission of a Phase 2a clinical trial protocol (Protocol…
MIRAMira Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. announced on June 17, 2026, the submission of a Phase 2a clinical trial protocol (Protocol Mira-002) for its proprietary oral NMDA receptor modulator, Ketamir-2, to the FDA for treating chemotherapy-induced peripheral neuropathy (CIPN). The FDA has acknowledged receipt of the submission. MIRA Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing proprietary NMDA receptor modulators for neurological and neurological-related disorders.